Is Intellia Therapeutics, Inc. (NTLA) a Buy, Sell, or Hold?
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$13.04 USD
-$0.26 (-1.95%)
- Volume
- 3.92M
- Average Volume
- 6.91M
- Market Capitalization
- $1.46B
- P/E Ratio
- -3.68
- Dividend Yield
- 0.00%
- Price Target
- $25.00
- Year High
- $28.25
- Year Low
- $7.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.10
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John Leonard |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NTLA |
| CUSIP | 45826J105 |
| CIK | 0001652130 |
| Web | https://www.intelliatx.com |
| Phone | 857 285 6200 |
| Currency | USD |
| Employees | 377 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.13 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.10 |
| Quick Ratio | 6.10 |
| Cash Ratio | 1.76 |
Sales & Book Value
| Annual Sales | $67.67M |
| Price / Sales | 22.14 |
| Cash Flow | -3.07 |
| Price / Cash Flow | -4.02 |
| Price / Book | 2.49 |
Price Target and Rating
| Average Stock Price Forecast | $25.00 |
| High Stock Price Forecast | $49.00 |
| Low Stock Price Forecast | $13.00 |
| Forecast Upside/Downside | -47.84% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 39 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.81 |
| Trailing P/E Ratio | -3.68 |
| PEG Ratio | -0.09 |
| P/E Growth | -0.09 |
| Net Income | $-412.69M |
| Net Margin | -597.04% |
| Pretax Margin | -597.04% |
| Return on Equity | -57.27% |
| Return on Assets | -52.00% |
Financials Score
| AltmanZ Score | 0.53 |
| Piotroski Score | 3.00 |
| Working Capital | 390M |
| Total Assets | 758.78M |
| Ebit | -394.6M |
| Market Cap | 1.49B |
| Total Liabilities | 137.84M |
Poll Results
About Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune diso ... rders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
2026-07-09 11:21:04
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
2026-07-08 05:45:00
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-06 16:05:00
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
2026-07-01 15:45:00
It might pull it off, provided several things fall right in place.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
2026-06-29 10:35:25
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
2026-06-20 11:02:04
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.
Dow Extends Record Run as Fed Decision Looms
2026-06-17 12:03:00
Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again
This Stock Is Up 58% This Year. Is It too Late to Buy?
2026-06-17 02:30:00
There could be additional catalysts for this drugmaker over the next year.
Frequently Asked Questions
-
What is the current Intellia Therapeutics, Inc. (NTLA) stock price?
-
Intellia Therapeutics, Inc.(NASDAQ:NTLA) stock price is $13.04 in the last trading session. During the trading session, NTLA stock reached the peak price of $28.25 while $7.95 was the lowest point it dropped to. The percentage change in NTLA stock occurred in the recent session was --1.95% while the dollar amount for the price change in NTLA stock was -$-0.26.
-
NTLA's industry and sector of operation?
-
The NASDAQ listed NTLA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NTLA?
-
John Leonard | President, Chief Executive Officer & Director
Rachel E. Haurwitz | Co-Founder
Luciano Marraffini | Founder and Member of Scientific Advisor Board
Derrick J. Rossi | Founder and Member of Scientific Advisor Board
Rodolphe Barrangou | Founder and Member of Scientific Advisor Board -
How many employees does NTLA have?
-
Number of NTLA employees currently stands at 377. NTLA operates from 40 Erie Street, Cambridge, MA 02139, US.
-
Link for NTLA official website?
-
Official Website of NTLA is: https://www.intelliatx.com
-
How do I contact NTLA?
-
NTLA could be contacted at phone #857 285 6200 and can also be accessed through its website. NTLA operates from 40 Erie Street, Cambridge, MA 02139, US.
-
How many shares of NTLA are traded daily?
-
The average number of NTLA shares traded daily for last 3 months was 6.91M.
-
What is the market cap of NTLA currently?
-
The market value of NTLA currently stands at $1.46B with its latest stock price at $13.04